<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657150</url>
  </required_header>
  <id_info>
    <org_study_id>1160.64</org_study_id>
    <secondary_id>2007-002630-11</secondary_id>
    <nct_id>NCT00657150</nct_id>
  </id_info>
  <brief_title>Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty</brief_title>
  <official_title>A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Compared to Subcutaneous 40 mg Enoxaparin Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Arthroplasty Surgery. (RE-NOVATE II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral
      dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily.
      Safety and efficacy will be compared between the treatment groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</measure>
    <time_frame>28-35 days</time_frame>
    <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</measure>
    <time_frame>28-35 days</time_frame>
    <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>28-35 days</time_frame>
    <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>28-35 days</time_frame>
    <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>28-35 days</time_frame>
    <description>Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pulmonary Embolism During Treatment Period</measure>
    <time_frame>28-35 days</time_frame>
    <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died During Treatment Period</measure>
    <time_frame>28-35 days</time_frame>
    <description>All cause death, as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</measure>
    <time_frame>3 months</time_frame>
    <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</measure>
    <time_frame>28-35 days</time_frame>
    <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding
gingival bleeding &gt;5 min
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Transfusion</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of treated and operated patients with required blood transfusion on day of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood Loss</measure>
    <time_frame>Day 1</time_frame>
    <description>Volume of blood loss for treated and operated patients during surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Analyses</measure>
    <time_frame>First administration to end of study</time_frame>
    <description>Frequency of patients with possible clinically significant abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2055</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>220 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>40 mg once daily</description>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate</intervention_name>
    <description>220 mg once daily</description>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients scheduled to undergo primary, unilateral, elective total hip arthroplasty.

          -  Male or female 18 years of age or older.

          -  Patients giving written informed consent for study participation.

        Exclusion criteria:

          -  Patients weighing less than 40 kg.

          -  History of bleeding diathesis.

          -  Patients who in the investigators judgement are perceived as having an excessive risk
             of bleeding, for example, constitutional or acquired coagulation disorders or because
             of anticipated need of quinidine, verapamil or other restricted medication during the
             treatment period (see Section 4.2.2).

          -  Major surgery or trauma (e.g., hip fracture) within 3 months of enrolment.

          -  Recent unstable cardiovascular disease (in the investigators opinion) such as
             uncontrolled hypertension, that is ongoing at the time of enrolment or history of
             myocardial infarction within 3 months of enrolment.

          -  Any history of haemorrhagic stroke or any of the following intracranial pathologies:
             bleeding, neoplasm, Atriovenous (AV) malformation or aneurysm.

          -  Ongoing treatment for Venous Thromboembolism (VTE).

          -  Clinically relevant bleeding (gastrointestinal, pulmonary, intraocular or urogenital
             bleeding) within 6 months of enrolment.

          -  Gastric or duodenal ulcer within one year of enrolment.

          -  Liver disease expected to have any potential impact on survival (ie, hepatitis B or C,
             cirrhosis). This does not include Gilberts syndrome or hepatitis A with complete
             recovery.

          -  Active liver disease or liver disease decreasing survival (e.g, acute hepatitis,
             chronic active hepatitis, cirrhosis) or Alanine Aminotransferase (ALT) &gt;3 x ULN.

          -  Known severe renal insufficiency (CrCl &lt;30 ml/min). Note: CrCl should be calculated
             only if serum creatinine is elevated or renal insufficiency is suspected. See Appendix
             10.1 for calculation.

          -  Elevated creatinine that, in the investigators opinion, contraindicates venography.

          -  Treatment with anticoagulants, clopidogrel, ticlopidine, abciximab, aspirin &gt;162.5
             mg/day or NSAID with t 1/2 &gt;12 hours within 7 days prior to hip replacement surgery OR
             anticipated need while the patient is receiving study medication and prior to 24 hours
             after the last administration of any blinded study medication (COX-2 selective
             inhibitors are allowed).

          -  Anticipated required use of intermittent pneumatic compression and electric
             stimulation of lower limb.

          -  Pre-menopausal women (last menstruation within 1 year prior to signing informed
             consent) who:

               -  Are pregnant.

               -  Are nursing.

               -  Are of child-bearing potential and are NOT practicing acceptable methods of birth
                  control, or do NOT plan to continue practicing an acceptable method throughout
                  the study. Acceptable methods of birth control include intrauterine device; oral,
                  implantable or injectable contraceptives and surgical sterility.

          -  Known allergy to radio opaque contrast media.

          -  History of thrombocytopenia, including heparin-induced thrombocytopenia, or a platelet
             count &lt;100,000 cells/microliter at randomisation.

          -  Allergy to heparins or dabigatran etexilate.

          -  Active malignant disease or current cytostatic treatment. Patients should be disease
             free for at least 5 years.

          -  Participation in a clinical trial within 30 days of randomisation.

          -  Leg amputee.

          -  Known alcohol or drug abuse which would interfere with completion of the study.

          -  Contraindications to enoxaparin.

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.64.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Conway</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daws Park</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box HIll</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.4004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.4002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.4003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.4001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.5004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.5002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deurne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.5005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lanaken</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.5001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton,</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belleville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stratford</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.6013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.7004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chomutov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.7005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jihlava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.7003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.7001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.7002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.8004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.8003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.8001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hørsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.8002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Markgröningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rheinfelden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Andhra Predesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baroda</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mohali</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ramdaspeth Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Secunderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.9113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vadodara</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1507 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1510 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1508 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.3001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takapuna Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tynset</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1705 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Piekary Slaskie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bryanston</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Western Province</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plumstead</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alcorcón (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuenlabrada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.1905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hässleholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kungälv</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lidköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Motala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.64.2107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>November 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2010</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The treatment period is from first administration of study medication, until 3 days after last administration of study medication. Treatment duration is planned for 28 - 35 days. The study period is from first administration of study medication until day 84 - 91.</recruitment_details>
      <pre_assignment_details>Whilst 2055 patients were randomised to treatment prior to surgery in this trial, only 2013 started treatment. Therefore, 42 patients were randomised but not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="P2">
          <title>Enoxaparin</title>
          <description>40mg qd (once daily) subcutaneous</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1010"/>
                <participants group_id="P2" count="1003"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="895"/>
                <participants group_id="P2" count="910"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1010"/>
                <participants group_id="P2" count="1003"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="903"/>
                <participants group_id="P2" count="906"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="B2">
          <title>Enoxaparin</title>
          <description>40mg qd (once daily) subcutaneous</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1010"/>
            <count group_id="B2" value="1003"/>
            <count group_id="B3" value="2013"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="11.5"/>
                    <measurement group_id="B2" value="62.0" spread="11.3"/>
                    <measurement group_id="B3" value="62.0" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="541"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="1042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="469"/>
                    <measurement group_id="B2" value="502"/>
                    <measurement group_id="B3" value="971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index N=(1003;992;1995)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="4.8"/>
                    <measurement group_id="B2" value="27.8" spread="4.8"/>
                    <measurement group_id="B3" value="27.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</title>
        <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
        <time_frame>28-35 days</time_frame>
        <population>Full Analysis Set (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, had evaluable negative venogram for both distal and proximal DVT in both legs or positive venography in any 1 segment of 1 or both legs, or confirmed symptomatic DVT, PE or death during the treatment period.)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</title>
          <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
          <population>Full Analysis Set (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, had evaluable negative venogram for both distal and proximal DVT in both legs or positive venography in any 1 segment of 1 or both legs, or confirmed symptomatic DVT, PE or death during the treatment period.)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="792"/>
                <count group_id="O2" value="786"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority Analysis with NI margin 7.7%</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Superiority p−value = 0.4367</p_value_desc>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.79</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</title>
        <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
        <time_frame>28-35 days</time_frame>
        <population>Full Analysis Set-major (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, had evaluable negative venogram for proximal DVT in both legs or a positive venogram for proximal DVT in either leg or confirmed symptomatic proximal DVT, PE or death related to VTE during the treatment period.)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</title>
          <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set-major (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, had evaluable negative venogram for proximal DVT in both legs or a positive venogram for proximal DVT in either leg or confirmed symptomatic proximal DVT, PE or death related to VTE during the treatment period.)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="805"/>
                <count group_id="O2" value="795"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</title>
        <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
        <time_frame>28-35 days</time_frame>
        <population>Full Analysis Set - pDVT (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery (i.e. a date of surgery was reported), evaluable negative venogram for proximal DVT in both legs or positive venogram in either leg or confirmed symptomatic proximal DVT)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</title>
          <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - pDVT (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery (i.e. a date of surgery was reported), evaluable negative venogram for proximal DVT in both legs or positive venogram in either leg or confirmed symptomatic proximal DVT)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="804"/>
                <count group_id="O2" value="793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0358</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.47</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</title>
        <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
        <time_frame>28-35 days</time_frame>
        <population>Full Analysis Set-tDVT (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, evaluable negative venogram for both distal and proximal DVT in both legs or positive venography in any 1 segment of 1 or both legs, or confirmed symptomatic DVT.)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</title>
          <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set-tDVT (randomised, had taken at least 1 dose of oral or subcutaneous trial medication, had undergone surgery, evaluable negative venogram for both distal and proximal DVT in both legs or positive venography in any 1 segment of 1 or both legs, or confirmed symptomatic DVT.)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="791"/>
                <count group_id="O2" value="784"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4839</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.65</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</title>
        <description>Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
        <time_frame>28-35 days</time_frame>
        <population>Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</title>
          <description>Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1001"/>
                <count group_id="O2" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0612</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pulmonary Embolism During Treatment Period</title>
        <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
        <time_frame>28-35 days</time_frame>
        <population>Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pulmonary Embolism During Treatment Period</title>
          <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1001"/>
                <count group_id="O2" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6231</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died During Treatment Period</title>
        <description>All cause death, as adjudicated by the VTE events committee</description>
        <time_frame>28-35 days</time_frame>
        <population>Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died During Treatment Period</title>
          <description>All cause death, as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op (all patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication or had undergone surgery (i.e. a date of surgery was reported)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1001"/>
                <count group_id="O2" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4977</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</title>
        <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
        <time_frame>3 months</time_frame>
        <population>Patients with any data available during follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</title>
          <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
          <population>Patients with any data available during follow-up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="951"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total VTE and all-cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asymptomatic Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>symptomatic Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6870</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</title>
        <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding
gingival bleeding &gt;5 min
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
        <time_frame>28-35 days</time_frame>
        <population>All patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</title>
          <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma &gt;=25 cm²
wound hematoma &gt;=100 cm²
spontaneous nose bleed &gt;5 min
macroscopic hematuria spontaneous or &gt;24 hours if associated with an intervention
spontaneous rectal bleeding
gingival bleeding &gt;5 min
any other bleeding event considered clinically relevant by the investigator
Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
          <population>All patients who had been randomised, had taken at least 1 dose of oral or subcutaneous trial medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1010"/>
                <count group_id="O2" value="1003"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major and clinically relevant bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any bleeding events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin for the category major bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4022</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absolute difference versus Enoxaparin for the category major and clinically relevant bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3305</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution</method_desc>
            <param_type>Absolute Difference (Percentage)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Absolute difference versus Enoxaparin for the category any bleeding events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2626</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution</method_desc>
            <param_type>Absolute Difference (Percentage)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Transfusion</title>
        <description>Number of treated and operated patients with required blood transfusion on day of surgery.</description>
        <time_frame>Day 1</time_frame>
        <population>Treated and operated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Transfusion</title>
          <description>Number of treated and operated patients with required blood transfusion on day of surgery.</description>
          <population>Treated and operated patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1001"/>
                <count group_id="O2" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Transfusions required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Blood Loss</title>
        <description>Volume of blood loss for treated and operated patients during surgery.</description>
        <time_frame>Day 1</time_frame>
        <population>Treated and operated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Blood Loss</title>
          <description>Volume of blood loss for treated and operated patients during surgery.</description>
          <population>Treated and operated patients</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="967"/>
                <count group_id="O2" value="957"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.9" spread="259.67"/>
                    <measurement group_id="O2" value="411.0" spread="275.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Analyses</title>
        <description>Frequency of patients with possible clinically significant abnormalities.</description>
        <time_frame>First administration to end of study</time_frame>
        <population>Treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin</title>
            <description>40mg qd (once daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Analyses</title>
          <description>Frequency of patients with possible clinically significant abnormalities.</description>
          <population>Treated patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="966"/>
                <count group_id="O2" value="962"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST increase N=(964;962)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST decrease N=(964;962)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increase N=(966;962)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT decrease N=(966;962)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin increase N=(966;962)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin decrease N=(966;962)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>31 - 38 days</time_frame>
      <desc>Treatment emergent events (last medication + 3 days)</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="E2">
          <title>Enoxaparin</title>
          <description>40mg qd (once daily) subcutaneous</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Fat embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Genital injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Oesophageal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="389" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="389" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="1003"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1010"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="1003"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

